Main content

    Breast Cancer Clinical Trials

    CPMC Cancer Services

    Oncology / Cancer Clinical Trials Main Page | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at ClinicalTrials.gov


    Active Trials

    Title: A Multicenter, Multinational, Phase II Study to Evaluate Pertuzumab in Combination With Trastuzumab and Standard Neoadjuvant Anthracycline-based Chemotherapy in Patients With HER2-Positive, Locally Advanced, Inflammatory, or Early-Stage Breast Cancer
    Description: This study study is designed to evaluate the safety and efficacy of Perjeta in combination with Herceptin and anthra cycline-based chemotherapy as neoadjuvant treatment in patients with HER2-based locally advanced, inflammatory, or early-stage breast cancer
    Investigator: Wei Wang, MD
    Eligibility: Male and female subjects, 18 y/o and older, with locally advanced, inflammatory, or early-stage, unilateral, and histologically confirmed invasive breast cancer. Patients with inflammatory breast cancer must be able to have a core needle biopsy
    Status: Active and open to enrollment
    Contact: Madeline Decker, 415-600-1775, Email: DeckerM@cpmcri.org about Study Genentech WO29217

    Title: A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients With Metastatic Breast Cancer
    Description: This randomized phase III trial is studying early surgery to see how well it works compared to standard palliative therapy in treating patients with stage IV breast cancer
    Investigator: NCI - National Cancer Institute
    Eligibility: Male and female subjects, 18 y/o and older, who have a diagnosis of intact primary (not recurrent) invasive carcinoma of the breast
    Status: Please contact site for study status
    Contact: Madeline Decker, 415-600-1775, Email: DeckerM@cpmcri.org about Study ECOG E2108

    A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less
    Description: RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
    Investigator: NCI - National Cancer Institute
    Eligibility: Female subjects, 18 y/o and older, who have a histologically confirmed diagnosis of node positive (1-3 nodes) invasive breast carcinoma with positive estrogen and/or progesterone receptor status, and negative HER-2 status; estrogen and progesterone receptor positivity
    Status: Please contact site for study status
    Contact: Madeline Decker, 415-600-1775, Email: DeckerM@cpmcri.org about Study SWOG S1007

    Title: A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Women With Early Stage Breast Cancer
    Description: This randomized phase III trial studies how well duloxetine hydrochloride works compared to a placebo in treating muscle, bone, and joint pain in patients with early-stage breast cancer receiving hormone therapy
    Investigator: NCI - National Cancer Institute
    Eligibility: Female subjects, 18 y/o and older, who have histologically confirmed estrogen receptor (ER)- and/or progesterone receptor (PgR)-positive invasive carcinoma of the breast with no evidence of metastatic disease (M0)
    Status: Please contact site for study status
    Contact: Madeline Decker, 415-600-1775, Email: DeckerM@cpmcri.org about Study SWOG S1202

    Title: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
    Description: This randomized phase III trial studies how well giving hormone therapy together with or without everolimus work in treating patients with breast cancer
    Investigator: NCI - National Cancer Institute
    Eligibility: Male and female subjects, 18 y/o and older, who have a histologically confirmed diagnosis of invasive breast carcinoma with positive estrogen (ER)- and/or progesterone-receptor (PR) status, and negative human epidermal growth factor receptor (HER)2, for whom standard adjuvant endocrine therapy is planned
    Status: Please contact site for study status
    Contact: Madeline Decker, 415-600-1775, Email: DeckerM@cpmcri.org about Study SWOG S1207

    Title: A Randomized Phase 3 Clinical Trial Evaluating Post-Mastectomy Chestwall & Regional Nodal XRT & Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemo Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemo
    Description: Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery
    Investigator: NCI - National Cancer Institute
    Eligibility: Female subjects, 18 y/o and older, who have clinically T1-3, N1 breast cancer at the time of diagnosis (before neoadjuvant therapy) and who have had pathologic confirmation of axillary nodal involvement at presentation (before neoadjuvant therapy)
    Status: Please contact site for study status
    Contact: Brenda Eng, 415-600-1775, Email: EngB@cpmcri.org about Study NSABP B-51

    Title: Randomized Double-Blind Placebo Controlled Study of Subcutaneous Testosterone in the Adjuvant Treatment of Postmenopausal Women With Aromatase Inhibitor Induced Arthralgias
    Description: Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment
    Investigator: NCI - National Cancer Institute
    Eligibility: Female subjects, 18 y/o and older, who have undergone a total mastectomy or breast-conserving surgery for primary breast cancer +/-chemotherapy and +/-radiotherapy
    Status: Please contact site for study status
    Contact: Brenda Eng, 415-600-1775, Email: EngB@cpmcri.org about Study Alliance A221102

    Title: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently With Radiation Therapy and Radiation Therapy Alone for Women With HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
    Description: Radiation therapy with or without Trastuzumab in treating women with ductal carcinoma in situ who have undergone lumpectomy
    Investigator: NCI - National Cancer Institute
    Eligibility: Female subjects, 18 y/o and older, who have a histologically confirmed ductal carcinoma in situ and who have unergone resection by lumpectomy
    Status: Please contact site for study status
    Contact: Brenda Eng, 415-600-1775, Email: EngB@cpmcri.org about Study NSABP B-43

    Title: A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node- Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
    Description: Chemotherapy with or without Trastuzumab after surgery in treating women with invasive breast cancer
    Investigator: NCI - National Cancer Institute
    Eligibility: Female subjects, 18 y/o and older, with a tumor that must be unilateral invasive adenocarcinoma of the breast on histologic examination
    Status: Please contact site for study status
    Contact: Brenda Eng, 415-600-1775, EngB@cpmcri.org about Study NSABP B-47

    Title: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
    Description: S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects, 18 y/o and older, who have a histologically confirmed diagnosis of invasive breast carcinoma, who have undergone axillary staging. And who have completed either breast-conserving surgery or total mastectomy
    Status: Please contact site for study status
    Contact: Brenda Eng, 415-600-1775, Email: EngB@cpmcri.org about Study SWOG S1207

    Title: A Phase II, Single Arm Study of the Use of Steroid-based Mouthwash to Prevent Stomatitis in Postmenopausal Women With Advanced or Metastatic Hormone Receptor Positive Breast Cancer Being Treated With Everolimus Plus Exemestane
    Description: Open-label, Phase II study of Stomatitis prevention with a steroid-based mouthwash in Post-menopausal women with ER+, HER2- Metastatic or Locally Advanced Breast Cancer
    Investigator: Wei Wang, MD
    Eligibility: Female subjects, 18 y/o and older, who have
    Status: Coming soon
    Contact: Madeline Decker, 415-600-1775, Email: DeckerM@cpmcri.org about Study Novartis STOPP

    • updated October 2014

    Back to top